What's Happening?
Biocartis, a molecular diagnostics company, and Discovery Life Sciences have announced a strategic collaboration to advance precision oncology diagnostics. This partnership will leverage Discovery's global clinical laboratory network and Biocartis's Idylla™
Platform, a rapid PCR-based system for molecular biomarker testing. The collaboration aims to provide pharmaceutical companies with faster and more efficient biomarker testing, facilitating patient enrollment in clinical trials. The initiative will initially focus on replicating a rapid KRAS testing program in the U.S., expanding the reach of precision diagnostics in oncology.
Why It's Important?
This collaboration is crucial for the advancement of precision medicine in oncology. By combining Biocartis's rapid testing capabilities with Discovery's extensive laboratory network, the partnership aims to streamline the process of identifying suitable patients for clinical trials. This could lead to more personalized treatment options for cancer patients, improving outcomes and potentially accelerating the development of new therapies. The ability to conduct harmonized testing across continents also ensures consistency in trial data, which is vital for global pharmaceutical programs.
What's Next?
The collaboration will focus on expanding the rapid KRAS testing program to the U.S. and developing additional biomarker testing capabilities. Both companies plan to co-develop service bundles and train their teams to support pharmaceutical partners. This initiative is expected to enhance the efficiency of global clinical trials and support the development of new companion diagnostics, ultimately benefiting cancer patients worldwide.
